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Abstract
Background: This study evaluated the efficacy and safety of the novel AspireAssist® Aspiration Therapy System for
treatment of obesity, and its effect on patient’s quality of life.
Methods: A prospective observational study with 25 obese subjects, mean age 48 years (range 33–65), was performed. A
custom gastrostomy tube (A-tube, Aspire Bariatrics) was percutaneously inserted during a gastroscopy performed under
conscious sedation. Drainage and irrigation of the stomach were performed 3 times daily, 20 min after each meal, for 1–2
years. Efficient aspiration required thorough chewing of ingested food. Treatment included a cognitive behavioral weight
loss program.
Results: Mean body mass index (BMI) at inclusion was 39.8 kg/m2 (range 35–49). After 1 year mean (SD) BMI was 32.
1 kg/m2 (5.4), p < 0.01, and excess weight loss was 54.4% (28.8), p < 0.01. Quality of life, as measured with EQ-5D,
improved from 0.73 (0.27) to 0.88 (0.13), p < 0.01. After 2 years BMI was 31.0 kg/m2 (5.1), p < 0.01, and excess weight
loss was 61.5% (28.5), p < 0.01. There were no serious adverse events or electrolyte disorders. Compliance was 80%
after 1 year and 60% after 2 years.
Conclusions: Aspiration therapy is an efficient and safe treatment for obesity, and weight reduction improves quality
of life. Excess weight was approximately halved in a year, with weight stability if treatment was continued.
Trial registration: Trial Register ISRCTN 49958132. Retrospectively registered 28/02/2014.
Keywords: Obesity treatment, Gastrostomy, Aspiration therapy
Background
Obesity, as defined by World Health Organization as
body mass index (BMI) greater than 30 kg/m2, is a
major global health problem with increasing prevalence.
Obesity has more than doubled worldwide since 1980.
In 2014, more than 1.9 billion adults, of 18 years and
older, were overweight. Most of the world’s population
live in countries where overweight and obesity cause
higher mortality than underweight [1]. In young and
middle age all-cause mortality risk appears to be directly
related to increase in BMI [2]. There is a well-
established association between obesity and decreased
quality of life [3] as well as morbidity from diabetes
mellitus type 2, elevated blood pressure, dyslipidemia
and cardiovascular complications as coronary artery
disease and cerebrovascular insult [4]. It has recently
been shown that obesity also is an avoidable cause of
some specific forms of cancer [5].
Alarmingly, it has been shown that obese mothers affect
the phenotype of their offspring, rendering the child more
susceptible to obesity. This effect is irreversible but
preventable by bariatric surgery prior to pregnancy [6, 7].
On the other hand, bariatric surgery before pregnancy
increases risk of preterm and small for gestational age
births [8].
Successful long-term weight loss is rarely achieved
through conservative treatment alone, even though there
are evidence of the moderate effectiveness of combin-
ation of psychological intervention, exercise and dietary
strategies [9]. Bariatric surgery is the most effective
therapy available today, with proven effects on long term
weight loss, mortality [10, 11], morbidity [12, 13] and
incidence of cancer in women [14].
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Bariatric procedures alter the anatomy of the gastro-
intestinal tract with the purpose of either restricting
caloric intake or reducing absorption of food nutrients.
All surgical procedures entail risks of complications. In
bariatric surgery these risks mainly comprises malab-
sorption and surgical complications related to leakage
from anastomoses or internal herniation of small bowel.
In recent years new endoscopic techniques have
emerged, thus providing less invasive options for treat-
ment of obesity [15, 16].
We evaluated a new device for treating obesity, the Aspir-
eAssist® Aspiration Therapy System (Aspire Bariatrics, King
of Prussa, PA), which consists of an endoscopically placed
gastrostomy tube and siphon assembly. AspireAssist® allows
patients to aspirate gastric contents 20 min after meal
consumption three times daily. Aspiration takes about
10 min to perform and removes approximately 30% of
ingested calories.
A pilot study by Sullivan et al. [17] reported signifi-
cantly greater loss of excess weight with Aspiration
Therapy in combination with lifestyle intervention, mean
49.0 (SEM 7.7)%, than lifestyle intervention alone, mean
14.9 (SEM 12.2)%, after 1 year follow-up. The authors
also concluded that aspiration therapy does not induce
any adverse eating behaviors or change baseline depres-
sion scores. All patients were supplemented with
potassium chloride (20 mmol orally daily) and started
on omeprazole (20 mg orally daily) to inhibit gastric
acid secretion.
Irrigation and aspiration of gastric content can
possibly lead to chronic loss of hydrogen and chloride
ions. The physiologic response is renal secretion of
potassium ions and resorption of hydrogen ions, result-
ing in hypochloremic hypokalemic metabolic alkalosis
[18, 19]. Loss of potassium ions cause hypokalemia and
risk of cardiac arrhythmia.
We have previously reported preliminary results of
treatment with 6 months follow-up [20]. The aim of the
current study was to evaluate weight loss, safety and
quality of life with AspireAssist® treatment for 1 to 2
years in obese subjects.
Methods
Study design
A single-center, observational, 1-year, prospective study
was conducted at the Department of Surgery at Blekinge
County Hospital in Karlskrona, Sweden. Power calcula-
tion for sample size was not performed due to lack of
published reports of AspireAssist®. This study was
designed as an initial exploratory study of safety and ef-
fectiveness. Subjects were consecutively recruited after
advertisement in local media. Inclusion criteria were
BMI ≥ 35.0 kg/m2 and age from 25 to 65 years. Exclusion
criteria were myocardial infarction during the last
3 months, known malignancy, chronic liver or kidney
disease, prior major surgery in the upper gastrointestinal
tract, psychiatric disease including substance abuse, eat-
ing disorder, mental retardation or other intellectual dis-
ability. Participants had the option to continue therapy
for an additional year.
Aim
The aim of the current study was to evaluate weight
loss, safety and quality of life with AspireAssist® treat-
ment for 1 to 2 years in obese subjects.
Subjects
Twenty-five obese subjects were enrolled between July
and September 2012. All subjects underwent interview
and medical examination. There were 23 women and
two men. Median age was 48 years (range 33–65). Base-
line comorbidities are presented in Table 1.
Study protocol
The components in the AspireAssist® Aspiration
Therapy System and the technique for endoscopic
placement of the A-tube are described by Sullivan et
al. [17]. Changes from the protocol used by Sullivan
et al. include addition of preoperative diet, use of
ultrasound, change in prophylactic antibiotics and
elimination of prophylactic prescription of potassium
and proton pump inhibitors.
Table 1 Comorbidities under treatment at baseline and after












Diabetes mellitus type 2 (total) 7 7 5
- Diet treatment 2 2 2
- Metformin 4 4 2
- Metformin + insulin 1 1 1
Hypertension (total) 9 8 7
- Diuretic 6 5 4
- ACE-inhibitor 5 5 4
- Beta receptor antagonist 3 3 3
Hyperlipidemia (total) 2 2 2
- Statin 2 2 2
Mood disorder (total) 9 6 6
- SSRI 8 6 6




- Omeprazole 2 2 3
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Preoperative diet
Consistent with the pre-surgical regimen for bariatric sur-
gery in Sweden, subjects were placed on a 4 week preopera-
tive very low calorie diet (VLCD) (Slanka, Slanka Sverige
AB, Sweden) providing approximately 680 kcal per day.
Preoperative diet reduces liver size [21] and thereby, theor-
etically, lowers the risk of iatrogenic liver damage.
Placement of the A-tube
The gastrostomy tube (the AspireAssist® A-tube) was
placed as a conventional pull percutaneous endoscopic
gastrostomy (PEG) and was performed under conscious
sedation (midazolam and ketobemidone). A standard
pull PEG set (Boston Scientific Europe, France) was
used. Careful evaluation of the optimal site for the place-
ment of the A-tube was performed in the epigastric part
of the abdomen with transillumination and finger inden-
tation at endoscopy. Bedside ultrasound examination
was performed to mark the border of the left liver lobe.
All patients received a postoperative prescription of
paracetamol and codeine.
Prophylactic antibiotics
Immediately after the procedure all patients received a sin-
gle dose of sulfamethoxazole and trimethoprim orally [22].
Placement of skin-port
Approximately 14 days after A-tube placement, allowing
the fistula to be formed, the tube was cut at the level of
the skin and a low-profile valve (the AspireAssist® Skin--
Port) was installed. The tube was subsequently short-
ened and the Skin-port readjusted following weight-loss.
Aspiration therapy
As reported by Sullivan et al. [17], subjects were
instructed to aspirate 20 min after breakfast, lunch, and
dinner. To prevent the tube from clogging when
attempting to aspirate, patients were instructed to chew
their food thoroughly. The AspireAssist® Connector
opens the valve and enables irrigation with tap water
and aspiration of gastric contents. The Connector
counts down after each connection and is disabled after
115 cycles, preventing additional aspirations, and hence
requires the subject to return to a healthcare profes-
sional to obtain a new Connector.
Cognitive behavioral therapy
Cognitive behavioral therapy (CBT) weight loss program
with elements of psychoeducation and mindfulness was
provided along with aspiration therapy by a CBT-certified
therapist and psychologist. Two sessions were performed
individually and six sessions were performed in group dur-
ing the initial 3 months of aspiration therapy. In total each
subject participated in eight sessions of CBT. In addition
to CBT each subject had seven appointments with the
project out-patient nurse for clinical control and cut-
ting of external excess tube length.
Assessment of quality of life
Quality of life was assessed by EuroQoL 5-dimension (EQ-
5D, http://www.euroqol.org) questionnaires and by a visual
analogue scale (VAS) of EQ-5D at baseline and at 52-weeks.
Electrolyte and pharmacological considerations
The risk of slowly developing intracellular potassium defi-
ciency regardless of normal potassium in blood samples mo-
tivated measurement of total potassium ion content in 24 h
urine samples to detect an increase in potassium losses. Six
subjects were on diuretics for blood pressure control and
were supplemented with oral potassium chloride 20 mmol,
daily. All subjects were instructed to administer any oral
medications after aspiration, or 2 h before aspiration.
Monitoring
Subjects had regular contact with the out-patient nurse;
initially four times during the first 3 months, thereafter
every 3 months. Blood and urine samples were collected
and weight registered every 3 months. Medical charts
were reviewed, and subjects were inquired for adverse
events, at each study visit. The Clavien-Dindo classifica-
tion of surgical complications [23, 24] was used for
grading of complications.
Statistical analysis
The statistical analysis was performed using Stata
version 14 (StataCorp LP, College Station, Texas, USA).
Skewness/Kurtosis test was used for normality assess-
ment. Parametric variables are presented as mean with
standard deviation (SD), and compared by two sample
student t test. Nonparametric variables are presented
as median with inter quartile range (IQR), and com-
pared with Wilcoxon matched-pairs signed-ranks test.
A two-sided p-value of ≤0.050 was considered statisti-
cally significant. Data in Fig. 2 and Table 2 is presented
both as “per protocol” (n = 25 at baseline, n = 20 at
12 months and n = 15 at 24 months) and as intension
to treat (n = 25) with the last registered value carried
forward.
BMI is calculated from body mass in kg divided with the
square of patient length in meters. Percent excess weight
loss is weight loss in percent exceeding BMI 25: ((baseline
BMI - BMI at measure point)/(baseline BMI - 25)) *100.
Results
Compliance
Twenty of the subjects (80%, one man and 19 women)
completed the intended 12-months of aspiration therapy
(Fig. 1). Five subjects withdrew from the study prior to
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1-year, primarily due to lack of motivation and unwill-
ingness to comply with the regimen. Sixteen subjects
experienced the Aspire method functioning and chosed
to continue treatment for a second year. One of the 16
subjects withdrew before completion of the second year.
In one case the proximal end of the A-tube had mi-
grated from the fundus of the stomach down into the
bulb of the duodenum and thereby constituting an outlet
obstruction which was consistent with the vomiting and
nausea reported by the patient. In all subjects that
aborted the treatment, the A-tubes were removed in a
secondary gastroscopy and the fistula closed spontan-
eously thereafter.
Frequency of aspirations was registered in a personal
diary during the first year of treatment. Aspiration three
times daily was reported for 76% of days for subjects in ac-
tive treatment. A detailed analysis of the diary data was
not performed, but a tendency was noted that weight loss
correlated with frequency of aspirations. Frequency of
aspirations was reduced after consistent weight loss.
Weight
Weight data is presented in Fig. 2 and Table 2. Mean
baseline weight was 107.4 kg (SD 18.7) and mean base-
line excess weight (defined as weight exceeding BMI 25)
was 40.2 kg (SD 13.8). Mean excess weight loss per
protocol was 54.4% (SD 28.8) at 12 months and 61.5%
(SD 28.5) at 24 months.
Procedure safety - electrolytes
Changes in electrolyte values during aspiration therapy
are presented in Table 3. There were neither significant
differences in serum potassium concentrations nor any
significant difference in total urinary secretion of potas-
sium in 24 h samples, as presented in Fig. 3. Urine
samples showed a trend of increasing pH in the urine,
indicating alkalization of urine, but the difference was
not statistically significant. Change of the urine pH value
is illustrated in Fig. 3.
Among the seven diabetic patients there was a signifi-
cant reduction in glycosylated hemoglobin type A1c
(HbA1c) level from median 47 (IQR 43–66) mmol/mol
to median 42 (IQR 36–64) mmol/mol, p = 0.03. Some of
the subjects were able to reduce or withdraw their oral
medications for diabetes, as presented in Table 1.
Procedure safety - complications
During the first postoperative week 13 subjects (52%) re-
ported moderate pain (relieved by analgesics) and three
subjects (9%) reported severe pain. Two were admitted
to hospital and underwent computed tomography due to
Fig. 1 Subject participation during 2 years with aspiration therapy
Fig. 2 Weight loss during 24 months aspiration therapy. Baseline is “-1 month” followed by 4 weeks very low calorie diet before insertion of A-tube at
“0 months”. Excess weight is weight exceeding BMI of 25. Data are presented as mean values with standard deviation. a Weight. b Body
Mass Index. c Excess weight loss
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suspicion of leakage or tube displacement. One subject
had no signs of leakage or displacement, and improved
promptly under observation. The other had a small
intraabdominal leakage at the gastrostomy site, a small
cavity with fluid was drained with ultrasound guidance
and subsequent culture was negative.
Three subjects reported additional adverse events
during the first 30 days postoperative. All of them were
stoma site related problems (one conservatively treated
skin irritation, one required antibiotics orally for bacterial
infection, and one had a small skin breakdown around the
stoma that resolved with conservative treatment).
In the subsequent 11 months one subject had a bacter-
ial infection at the stoma, treated with antibiotics orally.
Two subjects presented in the emergency department
with gallstones, one who also had pancreatitis. Both
underwent laparoscopic cholecystectomy.
According to the Clavien-Dindo grading system there
were one grade III-a, two grade II and three grade I
complications within 30 days and one more grade II
complication during the consequent 11 months. Postop-
erative pain was not classified as a complication if it did
not cause hospitalization. Gallstone diseases presented
early at a time where weight-loss was modest and were
hence not regarded as direct complications to the aspir-
ation therapy.
Quality of life
Subjects reported that quality of life, as measured with
EQ-5D and VAS, significantly increased during treat-
ment. This is presented in Table 3 and Fig. 4.
Discussion
The aim of this study was to evaluate weight reduction
and safety of aspiration therapy with AspireAssist™.
Twenty of our 25 subjects completed the initial 1 year
treatment. These 20 subjects lost mean 54% of their ex-
cess weight. At 2 years, 15 subjects had lost mean 61%




Baseline 12 months p 24 months p
Per protocol n = 25 n = 20 n = 15
Weight (kg) 107.4 (18.7) 86.1 (15.5) <0.01 83.4 (14.2) <0.01
BMI (kg/m2) 39.8 (4.3) 32.1 (5.4) <0.01 31.1 (5.1) <0.01
Excess weight (kg) 40.2 (13.8) 19.0 (14.8) <0.01 16.1 (13.7) <0.01
Excess weight loss (%) N.A. 54.4 (28.8) N.A. 61.5 (28.5) N.A.
Intention to treat
(Last value carried forward)
n = 25 n = 25 n = 25
Weight (kg) 107.4 (18.7) 88.4 (16.9) <0.01 89.3 (16.9) <0.01
BMI (kg/m2) 39.8 (4.3) 32.9 (5.3) <0.01 33.2 (5.2) <0.01
Excess weight (kg) 40.2 (13.8) 21.2 (14.9) <0.01 22.1 (14.8) <0.01
Excess weight loss (%) N.A. 44.5 (28.8) N.A. 44.9 (30.5) N.A.
Table 3 Results of 12 months aspiration therapy on quality of life,
blood and urine values and HbA1c level (the latter for diabetic
subjects only)








Visual Analogue Scale* 63 (15) 83 (14) <0.01
EuroQoL-5D* 0.73 (0.25) 0.88 (0.13) <0.01
Blood samples
Potassium (mmol/l) 4.4 (4.2–4.5) 4.3 (4.0–4.5) 0.57
Sodium (mmol/l) 140 (139–141.5) 141.5 (140–142) 0.02
Creatinine (umol/l) 62.5 (53–67) 68 (58.5–73.5) <0.01
Urine samples
24 h potassium (mmol) 66 (54–87) 57 (40.5–76.5) 0.10
24 h sodium (mmol) 203 (122–267) 147.5
(110.5–188.5)
0.02





Osmolality (mmol/kg) 482 (377–681) 394 (335–571) 0.30
pH 6.0 (5.5–6.7) 6.7 (6.2–7.0) 0.02






HbA1c (mmol/mol) 47 (43–66) 42 (36–64) 0.03
The five subjects who aborted treatment are excluded (presentation as per
protocol at 1 year). Data are presented as median (IQR) or mean (SD), the
latter indicated by *
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of their excess weight. This weight loss surpassed our
expectation and is nearly at the level of gastric bypass
procedure and other major abdominal surgery for obes-
ity. The subjects reported improved quality of life during
treatment. There was neither mortality nor any event
more severe than grade III-a according to Clavien-Dindo
grading system.
The hypothesis of a possible compensatory increase in
potassium secretion into urine, which could lead to
chronic hypokalemia and subsequent risk of cardiac
arrhythmia, was examined and rejected. We therefore
conclude that prophylactic administration of potassium
or proton pump inhibitors is unnecessary, if the patient
does not use any potassium lowering medication (as for
example diuretics). We also observed that aspiration
therapy caused alkalization of urine and a reduced
urinary secretion of chloride and sodium. We interpret
this as a compensatory response due to loss of some
hydrochloric acid.
Drainage of stomach content is only possible if the
patient eats slowly and chews thoroughly. The patient
gets a direct feedback regarding how well he or she
chewed when attempting aspiration. Many subjects
reported that the treatment has changed their eating
habits, with slower eating and smaller meals. This
change may in itself lead to a reduction in caloric in-
take. The previous study by Sullivan and his colleges
[17] indicates that the treatment does not lead to
increase in caloric intake.
Aspiration therapy requires patient cooperation, mak-
ing compliance integral to success. Treatment can be
intensified if there is indication of relapse with weight
Fig. 3 Change in urinary pH and electrolyte secretion during 12 months aspiration therapy. a Potassium secretion during 24 h. b Chloride
secretion during 24 h. c pH
Fig. 4 Change in quality of life during 12 months aspiration therapy. a EuroQoL 5-dimensions (EQ-5D). b Visual analogue scale
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gain. Today we have no means of predicting compliance,
but orderly persons with a capacity to follow daily
routines seem to have a higher probability of success. In
our study with 25 volunteers the drop out frequency was
20% the first study year, but 64% wanted to continue
treatment for a second year (Fig. 4). The participants in
our study reported an expected improvement in quality
of life, corresponding to weight loss, despite the pres-
ence of a gastrostomy and the need to perform drainage
of stomach contents three times daily.
Bariatric surgery is currently regarded as a golden
standard for obesity treatment. Aspiration therapy
provides a reversible, easily performed outpatient pro-
cedure that does not entail the risks associated with
major abdominal surgery. AspireAssist® does not alter
the anatomy of the gastrointestinal tract. In our experi-
ence so far, the AspireAssist® gastrostomy tube place-
ment has not complicated subsequent laparoscopic
bariatric surgery. One subject in our study underwent a
gastric bypass procedure without any problems related
to the prior gastrostomy stoma.
Limitation of this study is the combination of aspir-
ation therapy and CBT without any control group. This
study only encompasses treatment during 1 to 2 years.
Long term patency is still unknown. It is our belief that
once the desired weight goal is achieved many, if not
most, patients will need to continue aspiration therapy,
albeit possibly at a reduced frequency, to maintain
weight stability. In order to determine this we have
started a prospective study in which we will follow 50
patients with AspireAssist® and 50 patients with laparo-
scopic gastric bypass procedure for 5 years.
Conclusions
Aspiration therapy is a safe method that allows the
motivated obese patient to reduce his or her excess
weight by half, thus improving quality of life, in 1
year’s time. Long term results remain still to be
investigated.
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